Several molecular targeted therapies exist for other subtypes, including CDK4 inhibitors and MDM2 inhibitors for well-differentiated liposarcoma and dedifferentiated liposarcoma, and trabectedin for myxoid liposarcoma [1]. This evidence concerns the gene MDM2 and myxoid liposarcoma.